If you're reading this, then odds are you know that Venaxis Inc. (NASDAQ:APPY) shares are up a solid 10% today, while the market as a whole is in the red. What you may not know about APPY, however, is that with today's strength, the stock has worked its way past a big hurdle and put itself into a situation where more upside is very likely.
APPY is a medical diagnostic stock. Specifically, Venaxis had developed the APPY1 test, which is a rapid test to determine if certain symptoms are acute appendicitis or not.
It may seem minor - perhaps even meaningless - on the surface. After all, appendicitis is just the swelling of the appendix, which doesn't actually perform any known functions in the human body. Besides, it's not like doctors can't figure it out when appendicitis is present. For those more familiar with the condition though, they'll know that appendicitis is no laughing matter. There is (or was) no rapid test to determine if pain or symptoms are actually appendicitis, and since the affliction can quickly turn deadly if left untreated, the Venaxis rapid diagnostic is very much a big deal.
Best Defensive Stocks To Own For 2015: Uroplasty Inc (UPI)
Uroplasty, Inc., incorporated in January 1992, is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company�� primary focus is on two products: the Urgent PC Neuromodulation system and Macroplastique Implants. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence; and Macroplastique Implants a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company�� Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.
Urgent PC Neuromodulation System
Using a small-gauge needle electrode inserted above the ankle, the Urgent PC System delivers electrical impulses to the tibial nerve that travel to the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of the Urgent PC system include a hair-width needle electrode, a lead set, and an external, handheld, battery-powered stimulator. For each 30-minute, office-based therapy session, the physician or other qualified healthcare provider inserts the needle electrode in the patient�� lower leg and connects the electrode to the stimulator. Typically, a patient undergoes 12 consecutive weekly treatment sessions, with follow-up maintenance treatments as required to sustain the therapeutic effect. The Company has received regulatory clearances for sale of the Urgent PC system in the United States, Canada and Europe. It also has launched its second generation Urgent PC system.
Macroplastique
Macroplastique is designed to restore the patient�� urinary contine! nce immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. Macroplastique does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site. The Company has sold Macroplastique for several urological indications in over 40 countries outside the United States.
Other Uroplasty Products
The Company markets outside of the United States minimally invasive products to address fecal incontinence. Its PTQ Implants offer minimally invasive, soft-textured permanent implant for treatment of fecal incontinence. The PTQ Implants are implanted circumferentially into the submucosa of the anal canal, creating a bulking and supportive effect similar to that of Macroplastique injection for the treatment of stress urinary incontinence. The PTQ is Conformite Europeenne (CE) marked and is sold outside the United States in various international markets. The Urgent PC is also CE marked and sold outside of the United States for the treatment of fecal incontinence. In addition to urological applications, the Company markets its tissue bulking material outside the United States for otolaryngology vocal cord rehabilitation applications under the trade name VOX Implants. In the Netherlands and the United Kingdom only, the Company distributes certain wound care products in accordance with a distributor agreement.
The Company competes with Pfizer Inc., Johnson and Johnson, Novartis, Allergan, GlaxoSmithKline, Carbon Medical Technologies, BioForm, Inc., Q-Med AB and Contura.
Advisors' Opinion:- [By Lisa Levin]
Uroplasty (NASDAQ: UPI) shares reached a new 52-week high of $5.22 after the company reported strong Q3 results.
Juniper Networks (NYSE: JNPR) shares gained 8.23% to touch a new 52-week high of $28.15 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00.
10 Best Medical Stocks To Invest In Right Now: Haemonetics Corp (HAE)
Haemonetics Corporation, incorporated on August 29, 1985, is a healthcare company engaged in providing blood management solutions to its customers. The Company�� portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.
The Company helps its customers create and maintain a safe and efficient blood supply chain. Specifically, it develops and markets a wide range of systems used with plasma and blood donors that collect and process blood into its components using both manual and automated methods. It also develops and markets a variety of systems to hospitals that automate the cleaning and reinfusion of a surgical patient's blood during surgery, automate the tracking and distribution of blood in the hospital, and enhance blood diagnostics. The Company sells information technology platforms to promote efficient and compliant operations for all of its customer groups. The Company provides consulting services to reduce costs and improve operating efficiencies in blood management. . Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does.
Plasma
Human plasma is collected and processed by bio-ph! armaceutical companies into therapeutic and diagnostic products that aid in the treatment of immune diseases and coagulation disorders. While plasma is also used to aid patients with extreme blood loss, such as trauma victims, this portion of its business solely focuses on plasma's pharmaceutical uses. Automated plasma collection technology allows for the safe and efficient collection of plasma. The Company manufactures and market plasma collection devices and respective disposables, but do not make plasma-derived pharmaceuticals.
The Company�� portfolio of products and services is designed to support multiple facets of plasma collector operations. The Company with its PCS brand automated plasma collection technology, more plasma can be collected during any one donation event because the other blood components are returned to the donor through the sterile disposable sets used for the plasma donation procedure. The Company offers one stop shopping to its plasma collection customers, enabling them to source from them the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. It also offers a robust portfolio of integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain. Its products automate the donor interview and qualification process; streamline the workflow process in the plasma center; provide the controls necessary to evaluate donor suitability; determine the ability to release units collected; and manage unit distribution.
Blood Center
The Company offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products.The Company markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components integrated from the donor. Utilizing t! he MCS au! tomated platelet collection protocols, blood centers collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor. The MCS two-unit protocol or double red cell collection device helps blood collectors optimize the collection of red cells by automating the blood separation function, eliminating the need for laboratory processing, and enabling the collection of two units of red cells from a single donor thus maximizing the amount of red cells collected per eligible donor and helping to mitigate red cell shortages in countries where this problem exists. Blood collectors can also use the MCS system to collect one unit of red cells and a jumbo (double) unit of plasma, or one unit of red cells and one unit of platelets from a single donor. The MCS plasma protocol providing the possibility to collect 600-800ml of plasma for transfusion to patients or for pharmaceutical industry use completes the comprehensive portfolio of different blood component collection options on this device.
The Company offers a portfolio of products for manual whole blood collection and processing. Haemonetics' portfolio of disposable whole blood collection and component storage sets offer flexibility in collecting a unit of whole blood and the subsequent production and storage of the red blood cell, platelet, and/or plasma products, including options for in-line or dockable filters for leukoreduction of any blood component. In addition Acrodose product line provides a closed system for the pooling, storage, and bacteria testing of leukoreduced whole blood derived platelet concentrates, an Acrodose Platelet, that is transfusion ready for the hospital. Use of Acrodose platelets lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital.
The Company with ACP(Automated Cell Processor) brand offers a small bench-top solution to automate the washing and freezing of red cell components in the lab. The automated red cell was! hing proc! edure removes plasma proteins within the red cell units to provide a safer product for transfusion to frequently transfused patients, neonates, or patients with a history of transfusion reactions. The automated glycerolization and deglycerolization steps are required to prepare red cells for frozen storage. Freezing the red cell units can expand the shelf life of these products up to 10 years. Customers utilize this technology to implement strategic red cell inventories for catastrophe cases, storage of rare blood types, or enhanced inventory management.
Hospital
The Company offers a range of blood management solutions that significantly improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it efficiently and correctly. Its products and integrated solution platforms help hospitals optimize performance of blood acquisition, storage, and distribution.The Company�� TEG Thrombelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots.
The Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. During the year ended December 31,2012, the Company launched the Cell Saver Elite system, which is autotransfusion option to minimize allogeneic blood use for surgeries with medium to high blood loss. The OrthoPAT surgical blood salvage system is targeted to procedures, such as orthopedic, that involve slower, lower volume blood loss that often occurs well after surgery. The cardioPAT system is a surgical blood salvage system targeted to open heart surgeries when there is less blood loss during surgery, but where the blood loss continues post-surgery. These systems are designed to remain with the patient following surgery, to recover blood and produce a washed red cell produ! ct for au! totransfusion. Their Quick-Connect feature permits customers to utilize the blood processing set selectively, depending on the patient's need.
The Company�� IMPACT Online Web-based software platform, which monitors and measures improvements in a hospital�� blood management practices, provides hospitals with a baseline view of their blood management metrics and helps monitor transfusion rates. Business consulting solutions are offered to support process and blood management efforts. It also provides blood management assessment tools to hospitals that enables its customers to monitor their progress in order to continually improve their blood management performance.
Software Solutions
The Companby has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. For its plasma customers, it also provides information technology platforms for managing donors and information associated with the collection of plasma products within fractionation facilities.
The Company�� software solutions , including information technology platforms and consulting services can be combined with its devices and sold through its plasma, blood center, and hospital sales forces. The Company�� software products help hospitals track and safely deliver stored blood products. SafeTrace Tx is its software solution that helps manage blood product inventory, perform patient cross-matching, and manage transfusions. In addition, its BloodTrack suite of solutions manages tracking and control of blood products from the hospital blood center through to transfusion to the patient. Smart refrigerators located in or near operating suites, emergency rooms, and other parts of the hospital dispense blood units with secure control and autom! ated trac! eability for efficient documentation. With its offerings, hospitals are better able to manage processes across the blood supply chain and identify increased opportunities to reduce costs and enhance processes. Its software solutions, such as its SafeTrace and El Dorado Donor donation and blood unit management systems, span blood center operations and automate and track operations from the recruitment of the blood donor to the disposition of the blood product. Its Hemasphere software solution provides support for more efficient blood drive planning, and Donor Doc and e-Donor software help to improve recruitment and retention.
The Company competes with Fenwal, Inc., Terumo BCT ,Caridian BCT, Rotem, MAK Systems, Mediware, MacoPharma , Medtronic, Fresenius, Sunquest Information Systems and Sorin Biomedica.
Advisors' Opinion:- [By Holly LaFon]
Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power.
- [By shash63]
Haemonetics (HAE), pioneers in the blood-collection equipment market with around 75% market share in the U.S., is poised to capitalize on this market growth. For the fiscal 2014, Haemonetics reported revenue of $938.5 million, up 5%. Base revenue, exclusive of the whole blood business, increased 1% on a constant currency basis. To continue registering growth in this expanding market, the company is focusing on developing innovative solutions for managing blood with its acquisition strategy.
- [By Jake L'Ecuyer]
Haemonetics (NYSE: HAE) tumbled 1.13 percent to $42.06 after analysts at Benchmark downgraded the stock from Buy to Hold and lowered the target price from $49 to $46.
10 Best Medical Stocks To Invest In Right Now: ResMed Inc (RMD)
ResMed Inc., (ResMed), incorporated on March 31, 1994, is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. In December 2013, ResMed Inc acquired Unimedis SRO, a surgical appliance and manufacturing company.
Air Flow Generators
The Company produces continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP) and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full-face mask. Its VPAP units deliver bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. AutoSet systems are based on a technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. The Company�� Stellar 100 and 150 ventilation devices, provide both invasive and non invasive ventilation applications for adult and pediatric patients.
ResMed Inc.�� CPAP products include S8 Escape, S9 Elite and S9 Escape. Its VPAP products include VPAP III STA with QuickNav, VPAP S / VPAP IV, VPAP IV ST, S8 Auto 25, VPAP Tx Lab System, S9 VPAP S, S9 VPAP ST! , S9 VPAP Auto, S9 VPAP Adapt, S9 AutoSet CS, S9 Auto 25 and S9 VPAP COPD. The Company�� automatic positive airway pressure products include S9 AutoSet and S9 Escape Auto. Its ventilation products include Elisee 150, VS III and Stellar 100 and 150.
Masks, Accessories, Motors and Diagnostic Products
Masks, accessories, motors and diagnostic products together accounted for approximately 46% of its net revenues in fiscal 2012. Its Mask products include Activa LT, Swift LT for Her, Swift FX, Mirage SoftGel, Quattro FX, Swift FX for Her, Mirage FX, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Quattro Air and Swift FX Nano. Its diagnostic products includes ApneaLink + Oximetry and ApneaLink Plus (U.S.)
Accessories and Other Products
The Company to assist those professionals diagnosing or managing the treatment of patients have data communications and control products, such as the EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. These products include humidifiers, such as H5i and H4i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient, helping to prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. The Company�� data/patient management products include S9 Embletta Adapter, ResScan v3.14, ResTraxx v17.1., ResTraxx v18.3, ResScan v3.16 and EasyCare 1.0.
The Company competes with Philips BV, DeVilbiss Healthcare., Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corp, BMC Medical Co. Ltd and Weinmann Gerate fur Medizin GmbH + Co. KG.
Advisors' Opinion:- [By Jon C. Ogg]
ResMed�Inc. (NYSE: RMD) was raised to Buy from Neutral at BofA/Merrill Lynch.
Tyson Foods Inc. (NYSE: TSN) was downgraded to Neutral rom Buy at BofA/Merrill Lynch.
- [By Damian Illia]
A Delaware corporation formed in 1994, ResMed Inc. (RMD) is a global leading designer, developer, manufacturer and marketer of medical products for the diagnosis, treatment and management of sleep-disordered breathing (SDB) and other respiratory disorders. For the quarter ended in Dec. 31, 2013 ResMed reported a 2 percent increase (a 1 percent increase in constant currency basis) in revenue over the quarter ended in Dec. 31, 2012. However, these earnings failed to meet analyst estimates; and not without a reason. A relatively poor performance was expected due to continued pressure in the United States, especially as a consequence of the market's restructuring due to competitive Medicare bidding. This might also be one of the reasons why this stock still remains undervalued.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at ResMed (NYSE: RMD ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is ResMed doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 10.0%, and inventory decreased 9.3%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue increased 9.9%, and inventory shrank 9.3%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 1.9%, and inventory dropped 14.5%. - [By Roberto Pedone]
Another earnings short-squeeze prospect is medical equipment player ResMed (RMD), which is set to release numbers on Wednesday after the market close. Wall Street analysts, on average, expect ResMed to report revenue of $400.01 million on earnings of 64 cents per share.
The current short interest as a percentage of the float for ResMed is extremely high at 25.6%. That means that out of the 139.26 million shares in the tradable float, 35.89 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 5%, or by about 1.72 million shares. If the bears get caught pressing their bets into a bullish quarter, then shares of RMD could easily trend sharply higher post-earnings as the shorts rush to cover some of their positions.
From a technical perspective, RMD is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. Shares of RMD have started to flirt with a near-term breakout trade today, since the stock has tested some past overhead resistance at $48.07 a share. That move is starting to push shares of RMD within range of triggering a much bigger breakout trade post-earnings.
If you're bullish on RMD, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some key overhead resistance levels at $51.22 to $51.32 share with high volume. Look for volume on that move that hits near or above its three-month average action of 1.17 million shares. If that breakout hits post-earnings, then RMD will set up to re-fill some of its previous gap-down-day zone from October of 2013 that started just above $56 a share. If that gap gets filled with strong upside volume flows, then RMD could easily trend north of $60 a share.
I would simply avoid RMD or look for short-biased trades if after earnings
10 Best Medical Stocks To Invest In Right Now: Biomerieux SA (BIM)
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, such as bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, bioMerieux Benelux SA/NV, among others. In January 2014, it acquired 100% stake in BioFire Diagnostics Inc. Advisors' Opinion:- [By Jonathan Morgan]
BioMerieux (BIM) jumped 3.8 percent to 76.53 euros, the largest gain in eight months. The French maker of tests for HIV and hepatitis reported sales for the first half of 754 million euros and confirmed its revenue-growth forecast.
10 Best Medical Stocks To Invest In Right Now: Hemispherx Biopharma Inc (HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.
Ampligen
Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.
Alferon N Injection
Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.
Alferon LDO (Low Dose Oral)
Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.
The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.
Advisors' Opinion:- [By MONEYMORNING]
Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.
10 Best Medical Stocks To Invest In Right Now: Receptos Inc (RCPT)
Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.
As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.
As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.
Advisors' Opinion:- [By RichardCox]
For those willing to take on some added volatility (and potential for increased risk based on less diversification), investors can look at Receptos Inc. (RCPT), to play this year's momentum in IPO entries. Enhanced expectations for the company's IPO drove the company to raise its initial share offering to 5.2 million shares. Receptos has reached late-stage development for its oral treatment for multiple sclerosis (MS). MS treatments are dominated by industry heavyweights but MS pills are expected to surge in the next few years because oral treatments are becoming more efficient than injected therapies, and can cater to a broader consumer base. Being a new company, the Receptos chart only offers limited incite, and will not be included here.
- [By Roberto Pedone]
Receptos (RCPT) is a biopharmaceutical company engaged in discovering, developing and commercializing therapeutics for immune disorders. This stock closed up 5% at $23.19 in Monday's trading session.
Monday's Volume: 69,000
Three-Month Average Volume: 55,356
Volume % Change: 50%From a technical perspective, RCPT ripped higher here right above some key near-term support at $21 with decent upside volume. This move is quickly pushing shares of RCPT within range of triggering a major breakout trade. That trade will hit if RCPT manages to take out its all-time high at $25 with high volume.
Traders should now look for long-biased trades in RCPT as long as it's trending above support at $21 and then once it sustains a move or close above its all-time high at $25 with volume that's near or above 55,356 shares. If that breakout hits soon, then RCPT will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $30 to $35.
- [By John Udovich]
Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
10 Best Medical Stocks To Invest In Right Now: International Stem Cell Corp (ISCO)
International Stem Cell Corporation, incorporated on June 7, 2005 is a developmental-stage biotechnology company. The Company focused on therapeutic and biomedical product development. The Company�� wholly owned subsidiary Lifeline Cell Technology, LLC (LCT) develops, manufactures and commercializes over 130 human cell culture products, including frozen human primary cells and the reagents (media) needed to grow, maintain and differentiate the cells, in order to address this market opportunity. The Company�� scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. The Company�� wholly owned subsidiary Lifeline Skin Care, Inc. (LSC) develops, manufactures and markets cosmetic skin care products using an extract derived from its pluripotent stem cells.
Therapeutic Product Candidates
Using the Company's technologies and know-how, the Company is exploring and creating a range of cell types that is useful in therapeutic treatments, which include Liver cells (hepatocytes) that may be used to treat a range of congenital and acquired liver diseases. Neuronal cells for potential treatment of Parkinson's disease and other central nervous system disorders, such as traumatic brain injury, stroke and Alzheimer�� disease. Three-dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to accelerate corneal healing.
Skin Care Products
The Company�� research scientists developed two skin care products, Defensive Day Serum and Recovery Night Serum, using an extract derived from human parthenogenic stem cells. Defensive Serum contains sunscreen, along with stem cell-derived ingredients. The day serum not only protects the skin from the aging effects of harsh light, but it continues to nurture the skin�� collagen and fibroblasts to give noticeably firmer, smoother, younger-looking ! skin. The Recovery Night Serum is a nighttime therapy that complements the Defensive Day Serum. The night serum nurtures the skin�� collagen and elastin and contains ingredients to defend against damaging free radicals, to help build firmer, smoother, younger and healthier-looking skin.
Research Products
The Company�� Lifeline subsidiary produces and sells over 250 human cell culture products. These products include frozen human cells and stem cells and the reagents needed to grow, maintain and differentiate the cells. These human cell-based products are used domestically and internationally by research scientists in pharmaceutical, academic and government research organizations to study human disease and basic cell biology.
The Company competes with Genzyme Corporation, StemCell, Advanced Cell Technology Inc., Aastrom Biosciences, ViaCyte, Obagi, SkinCeuticals, SkinMedica, Murad, Lonza, Chemicon, Life Technologies, StemCell Technologies, Merck, BioTime and Specialty Media.
Advisors' Opinion:- [By John Udovich]
Stem cells may not be in the news much�as the sector has moved beyond the use of embryotic�ones, but small cap stem cell stocks Cellular Dynamics International Inc (NASDAQ: ICEL), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been fairly active over the past several trading days as ICEL went public, ISCO raised additional funding and BRTX grabbed more attention:
- [By John Udovich]
The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.
- [By Peter Graham]
Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:
- [By John Udovich]
From stem cell burgers to earnings reports, the stem cell industry and small cap players in it like NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been producing some news lately that has probably been overlooked by investors and traders alike given its August. Nevertheless, you might want to pay attention to the following stem cell news:
No comments:
Post a Comment